Evidence map›Paper›PMID 38069406›Full record

ArticleInternational journal of molecular sciences2023

Ubiquitination of Major Histocompatibility Complex II Changes Its Immunological Recognition Structure.

Yuko Kozono, Masahiro Kuramochi, Yuji C Sasaki, Haruo Kozono

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Exploring new frontiers in LAG-3 biology and therapeutics.Trends in pharmacological sciences · 2025
    Review
  3. Pain mechanism and management strategy of rheumatoid arthritis.Frontiers in pain research (Lausanne, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Yuko KozonoResearch Institute for Biomedical Sciences, Tokyo University of Sciences, Noda 278-0022, Chiba, Japan.
Masahiro KuramochiGraduate School of Science and Engineering, Ibaraki University, Hitachi 316-0033, Ibaraki, Japan.ORCID 0000-0003-1643-3997
Yuji C SasakiDepartment of Advanced Material Science, Graduate School for Frontier Sciences, The University of Tokyo, Kashiwa 277-8568, Chiba, Japan.ORCID 0000-0003-3403-237X
Haruo KozonoResearch Institute for Biomedical Sciences, Tokyo University of Sciences, Noda 278-0022, Chiba, Japan.ORCID 0000-0003-3352-0638
Tokyo University of Science · JPIbaraki University · JPSPring-8 · JP

Funding

Japan Agency for Medical Research and Development JP23zf0127004Japan Society for the Promotion of Science JP23K06600
6 · The paper itself

Abstract

Ubiquitination is a process that dictates the lifespan of major histocompatibility complex class II (MHC II)/peptide complexes on antigen-presenting cells. This process is tightly controlled by the levels of ubiquitin ligases, and disruptions in the turnover of MHC II can lead to the improper development of CD4+ T cells within the thymus and hinder the formation of regulatory T cells in the peripheral tissue. To investigate the underlying mechanisms, we utilized dendritic cells lacking the Membrane-associated RING-CH (MARCH) I ubiquitin ligase. We discovered that the overexpression of MARCH I decreases the interaction with LAG-3. Moreover, the MHC II molecules tethered with ubiquitin also showed diminished binding to LAG-3. We employed Diffracted X-ray Blinking (DXB), a technique used for single-molecule X-ray imaging, to observe the protein movements on live cells in real time. Our observations indicated that the normal MHC II molecules moved more rapidly across the cell surface compared to those on the MARCH I-deficient dendritic cells or MHC II KR mutants, which is likely a result of ubiquitination. These findings suggest that the signaling from ubiquitinated MHC II to the T cell receptor differs from the non-ubiquitinated forms. It appears that ubiquitinated MHC II might not be quickly internalized, but rather presents antigens to the T cells, leading to a range of significant immunological responses.

Indexed as

Dendritic CellsUbiquitin-Protein LigasesHistocompatibility Antigens Class IIMajor Histocompatibility ComplexUbiquitinUbiquitinationHistocompatibility Antigens Class IIUbiquitinUbiquitin-Protein Ligasesdendritic cellsLAG-3MHCsingle-molecule biophysicsubiquitin ligase

Identifiers

PMID38069406
PMCPMC10707457
OpenAlexW4389286314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.